Inhibiting the excessive expression of the AR holds significant promise in attenuating RCC’s initiation, proliferation, invasion, and metastasis, along with alleviating resistance to sunitinib, a current therapeutic approach to metastatic RCC that uses tyrosine kinase receptor inhibitors. Here, NTRK1 is linked to renal cell carcinoma.